Hub : Traits :

Medication: Blood pressure

311 significantly associated models · 116 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 11181327 12600396 1 1 2.6e-09 1.2e-12 6.4e-05 68 CLCN6
2 1 26428864 27820430 1 1 4.2e-08 9.2e-06 2.2e-01 92 PIGV
3 1 88621347 90053563 1 1 7.8e-09 2.2e-08 1.1e-01 92 GTF2B
4 1 112312154 114196883 6 2 2.0e-11 4.0e-15 1.9e-04 78 WNT2B
5 1 230142626 231548480 1 1 3.0e-14 1.4e-13 1.0e+00 100 AGT
6 2 24021231 25692112 1 1 4.9e-08 5.2e-07 2.7e-07 -5 NCOA1
7 2 26223547 27689899 2 2 5.5e-09 5.5e-26 4.7e-17 37 KCNK3 SLC35F6
8 2 215101843 216697115 1 1 1.2e-07 2.2e-04 8.6e-03 50 ABCA12
9 3 26720690 28211713 1 1 3.9e-08 2.7e-09 2.3e-02 85 SLC4A7
10 3 137189600 138819532 2 1 5.7e-08 1.7e-07 1.0e+00 100 DBR1
11 3 168814909 170228362 1 1 3.9e-07 2.1e-07 2.1e-07 0 LRRC34
12 4 80488345 82578407 2 1 1.4e-09 2.7e-26 3.0e-18 33 C4orf22
13 5 130830617 132425049 5 1 7.7e-08 8.2e-08 1.0e+00 100 SLC22A5
14 6 33856903 35362848 1 1 1.0e-07 5.3e-05 2.9e-02 71 C6orf106
15 6 42611872 44034691 1 1 5.4e-10 6.7e-10 1.0e+00 100 ZNF318
16 6 125970401 128536730 2 2 1.1e-11 4.7e-20 6.1e-08 65 C6orf174 CENPW
17 7 6502367 7988091 1 1 9.4e-10 1.0e-07 6.3e-01 99 C1GALT1
18 7 129917130 131315092 1 1 3.1e-11 3.8e-14 3.0e-06 62 RP11-138A9.1
19 8 8092025 13120332 17 2 1.4e-09 2.8e-10 9.5e-03 83 ERI1 NEIL2
20 10 103987875 105647095 2 1 2.1e-08 4.4e-09 7.9e-02 91 NT5C2
21 11 1213806 2705175 3 3 1.2e-14 8.7e-17 4.0e-02 94 LSP1 TNNT3
22 11 46570859 47977454 2 1 3.3e-09 4.8e-08 3.6e-01 97 ACP2
23 11 64860655 66262606 1 1 3.5e-07 3.8e-09 7.6e-04 67 OVOL1
24 11 99859184 101559718 2 1 4.4e-19 3.7e-19 1.0e+00 100 ARHGAP42
25 11 106500377 108027561 1 1 2.0e-07 4.7e-07 2.0e-02 79 CWF19L2
26 12 111154626 113517494 10 1 1.4e-11 9.8e-16 1.6e-06 64 SH2B3
27 13 29386474 31108727 2 2 6.8e-08 9.8e-10 4.3e-02 89 SLC7A1 UBL3
28 15 74042497 76108550 10 1 9.1e-11 9.5e-11 6.6e-02 92 MPI
29 15 80377452 81936479 1 1 2.0e-09 1.5e-10 2.4e-02 88 KIAA1199
30 15 90712555 92135418 2 1 3.7e-17 4.8e-17 3.2e-02 94 FES
31 16 3969463 5510848 3 1 5.0e-11 3.7e-10 1.7e-03 75 MGRN1
32 16 89013848 90172696 8 1 3.5e-12 1.9e-12 6.7e-02 93 CDK10
33 17 6644945 8484683 3 2 2.8e-08 5.7e-08 7.1e-01 100 CYB5D1 FGF11
34 17 42607368 43913030 6 2 1.2e-08 3.1e-07 9.8e-01 100 FMNL1 LRRC37A4P
35 17 44788310 45510971 2 1 9.4e-08 1.2e-06 1.8e-01 92 NSF
36 17 60858059 62259376 1 1 4.4e-08 1.1e-08 1.0e+00 100 ACE
37 17 78665405 80023050 1 1 9.4e-08 8.9e-08 3.3e-01 97 RP11-1055B8.4
38 19 16462417 18007950 2 1 4.2e-09 1.6e-08 9.7e-03 79 MYO9B
39 20 7419920 9648826 1 1 1.9e-07 6.4e-13 6.8e-07 52 PLCB1
40 20 61522825 62912463 3 2 8.7e-09 2.1e-08 1.0e+00 100 LIME1 ZBTB46
41 22 28493429 29894210 1 1 3.3e-07 1.6e-08 1.5e-02 81 XBP1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (in father) 1.1 1 0 0.0 0.00 1.0e+00 ACE
Alzheimer’s Disease (including proxy) 1.3 1 1 3.0 0.00 1.0e+00 ACE
Crohns Disease (2017) 2.2 1 1 3.0 0.00 1.0e+00 SLC22A5
Irritable Bowel Disease (IBD) 1.8 1 1 3.0 0.00 1.0e+00 SLC22A5
Ulcerative Colitis (UC) 1.2 1 0 0.0 0.00 1.0e+00 SLC22A5
Major Depression (MDD) 1.9 1 0 0.0 0.00 1.0e+00 FES
Reaction Time 1.3 1 1 3.0 0.00 1.0e+00 SH2B3
Breast Cancer 5.0 9 5 15.2 -0.21 5.9e-01 FES FMNL1 LRRC37A4P LSP1 MPI NSF SLC22A5 SLC4A7 TNNT3
Ovarian Cancer 2.0 2 1 3.0 0.00 1.0e+00 LRRC37A4P NSF
Prostate Cancer 2.1 1 0 0.0 0.00 1.0e+00 TNNT3
Body Mass Index (BMI) (2010) 1.7 1 0 0.0 0.00 1.0e+00 NT5C2
Coronary Artery Disease (CAD) 2.6 3 1 3.0 0.00 1.0e+00 C6orf106 DBR1 SH2B3
Crohns Disease (2012) 1.9 1 1 3.0 0.00 1.0e+00 SLC22A5
Fasting Glucose 1.6 1 1 3.0 0.00 1.0e+00 ACP2
HDL Cholesterol 2.3 4 3 9.1 1.00 1.3e-03 ACP2 C6orf106 PIGV RP11-138A9.1
LDL Cholesterol 2.0 4 0 0.0 0.64 3.6e-01 C6orf106 MPI PIGV SH2B3
Lupus 1.6 1 0 0.0 0.00 1.0e+00 ERI1
Neuroticism 3.0 5 2 6.1 0.99 5.0e-04 ERI1 FMNL1 LRRC37A4P NEIL2 NSF
Primary Biliary Cirrhosis 1.9 3 1 3.0 0.00 1.0e+00 FMNL1 LRRC37A4P SH2B3
Rheumatoid Arthritis 1.2 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia 2.2 4 2 6.1 0.93 6.9e-02 CDK10 FES NT5C2 XBP1
Triglycerides 1.5 2 0 0.0 0.00 1.0e+00 ERI1 NEIL2
Type 2 Diabetes (T2D) 1.5 1 0 0.0 0.00 1.0e+00 RP11-138A9.1
Blood Eosinophil Count 7.0 9 8 24.2 -0.66 5.4e-02 FMNL1 LRRC34 LRRC37A4P NSF OVOL1 PIGV RP11-138A9.1 SH2B3 SLC22A5
Blood Platelet Count 2.3 16 10 30.3 -0.48 5.3e-02 CDK10 CLCN6 GTF2B LIME1 MGRN1 MPI MYO9B OVOL1 PIGV PLCB1 SH2B3 SLC22A5 SLC4A7 TNNT3 WNT2B ZNF318
Blood Red Count 3.7 19 11 33.3 0.13 6.0e-01 C4orf22 C6orf174 CDK10 CENPW CLCN6 CYB5D1 FMNL1 GTF2B LRRC37A4P MGRN1 MPI NCOA1 NSF NT5C2 RP11-138A9.1 SH2B3 SLC35F6 XBP1 ZBTB46
Blood White Count 3.5 18 6 18.2 -0.46 5.4e-02 ABCA12 ARHGAP42 CDK10 CYB5D1 FES FMNL1 GTF2B KCNK3 KIAA1199 LRRC37A4P MGRN1 NT5C2 PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6
Heel T-Score 3.6 15 13 39.4 -0.05 8.5e-01 ACP2 ARHGAP42 C6orf174 CYB5D1 FMNL1 GTF2B LIME1 LRRC37A4P NCOA1 NSF NT5C2 OVOL1 WNT2B XBP1 ZNF318
BMI 1.7 9 4 12.1 -0.40 2.9e-01 C4orf22 C6orf106 CLCN6 CYB5D1 KCNK3 KIAA1199 NT5C2 SLC35F6 ZNF318
Height 2.1 25 18 54.5 0.25 2.2e-01 ACE ACP2 ARHGAP42 C6orf106 CENPW DBR1 FES FGF11 GTF2B LRRC37A4P LSP1 MGRN1 NCOA1 NSF NT5C2 OVOL1 PIGV RP11-1055B8.4 SH2B3 SLC22A5 SLC35F6 SLC4A7 TNNT3 WNT2B ZNF318
Waist Hip Ratio (WHR) 3.1 11 8 24.2 0.08 8.2e-01 C6orf174 CENPW DBR1 FGF11 GTF2B LRRC37A4P MYO9B NCOA1 NSF RP11-138A9.1 ZNF318
Systolic Blood Pressure 16.1 42 35 106.1 -0.95 1.0e-22 ABCA12 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf174 CENPW CLCN6 CWF19L2 CYB5D1 DBR1 FES FGF11 FMNL1 GTF2B KIAA1199 LIME1 LRRC37A4P LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 OVOL1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC4A7 SLC7A1 TNNT3 UBL3 WNT2B XBP1 ZBTB46 ZNF318
Smoking Status 1.6 3 0 0.0 0.00 1.0e+00 C6orf106 FES KIAA1199
Allergy or Eczema 2.0 8 2 6.1 0.07 8.6e-01 C6orf106 CLCN6 FES LIME1 MPI OVOL1 SH2B3 SLC22A5
Cardiovascular Disease 14.3 44 33 100.0 -0.97 6.9e-28 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 C6orf174 CDK10 CENPW CLCN6 CWF19L2 CYB5D1 DBR1 FES FGF11 FMNL1 GTF2B KCNK3 KIAA1199 LIME1 LRRC34 LSP1 MGRN1 MPI MYO9B NCOA1 NSF NT5C2 OVOL1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 UBL3 WNT2B ZBTB46 ZNF318
Hypothyroidism (self reported) 3.3 1 1 3.0 0.00 1.0e+00 SH2B3
Respiratory disease 2.0 4 1 3.0 -0.54 4.6e-01 FES FGF11 LIME1 SLC22A5
Type 2 Diabetes (T2D) 2.5 6 1 3.0 -0.99 1.1e-04 ACE C1GALT1 DBR1 RP11-138A9.1 SH2B3 ZBTB46
Lung FEV1/FVC ratio 1.5 8 4 12.1 0.48 2.3e-01 ARHGAP42 C1GALT1 C6orf106 C6orf174 CENPW LRRC37A4P NSF SLC22A5
Lung FVC 3.1 15 6 18.2 -0.40 1.4e-01 ABCA12 C6orf106 CENPW DBR1 FGF11 FMNL1 LRRC37A4P NCOA1 NSF NT5C2 RP11-1055B8.4 SH2B3 SLC22A5 WNT2B ZBTB46
Neuroticism 3.2 7 4 12.1 -0.11 8.1e-01 ACP2 C1GALT1 FGF11 FMNL1 LRRC37A4P NSF NT5C2
Hair Pigment 9.6 12 5 15.2 -0.31 3.3e-01 ACP2 ARHGAP42 C4orf22 C6orf106 CDK10 DBR1 FES LRRC37A4P OVOL1 PIGV RP11-138A9.1 SH2B3
Tanning 10.6 3 1 3.0 0.00 1.0e+00 CDK10 CLCN6 SH2B3
Hand grip strength (left) 2.1 5 3 9.1 -0.35 5.7e-01 FES LRRC37A4P MGRN1 NSF SLC22A5
Number of treatments/medications taken 5.0 11 2 6.1 0.98 6.4e-08 ACE ARHGAP42 C1GALT1 C6orf106 CWF19L2 KIAA1199 MGRN1 NCOA1 OVOL1 SH2B3 SLC22A5
Sensitivity / hurt feelings 3.8 6 4 12.1 -0.94 4.5e-03 ERI1 FES FMNL1 LRRC37A4P NEIL2 NSF
Frequency of depressed mood in last 2 weeks 1.6 1 0 0.0 0.00 1.0e+00 NSF
Hearing difficulty/problems: Yes 1.7 1 1 3.0 0.00 1.0e+00 ZNF318
Relative age of first facial hair 3.7 5 4 12.1 -0.65 2.4e-01 C4orf22 FMNL1 LRRC37A4P NSF XBP1
Systolic blood pressure, automated reading 11.8 32 26 78.8 0.97 5.5e-22 ABCA12 ACP2 AGT ARHGAP42 C4orf22 C6orf174 CLCN6 CWF19L2 DBR1 ERI1 FES FGF11 FMNL1 GTF2B KIAA1199 LIME1 LRRC37A4P LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 PIGV RP11-1055B8.4 SH2B3 SLC4A7 TNNT3 WNT2B ZBTB46
Angina 2.5 2 1 3.0 0.00 1.0e+00 FES ZBTB46
Vitamin and mineral supplements 1.3 1 0 0.0 0.00 1.0e+00 NSF
Medication: Metformin 1.8 3 0 0.0 0.00 1.0e+00 DBR1 RP11-138A9.1 ZBTB46
Impedance of leg (right) 2.4 16 9 27.3 -0.08 7.6e-01 ARHGAP42 C6orf106 CENPW ERI1 FES FMNL1 KCNK3 KIAA1199 LRRC37A4P MYO9B NEIL2 NSF NT5C2 SLC35F6 WNT2B ZNF318
Leg fat-free mass (left) 2.3 13 6 18.2 0.12 7.1e-01 ARHGAP42 C6orf106 CENPW ERI1 FES KCNK3 KIAA1199 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Trunk fat percentage 2.4 12 7 21.2 0.17 6.1e-01 C6orf106 CDK10 DBR1 FGF11 FMNL1 KCNK3 LRRC37A4P MYO9B NSF NT5C2 RP11-138A9.1 WNT2B
Hand grip strength (right) 2.0 6 1 3.0 -0.43 3.9e-01 CWF19L2 FGF11 LRRC37A4P NSF SLC22A5 WNT2B
Fed-up feelings 2.3 7 2 6.1 -0.64 1.2e-01 ACP2 ERI1 FMNL1 LRRC37A4P NEIL2 NSF SH2B3
Relative age voice broke 2.5 3 3 9.1 0.00 1.0e+00 FMNL1 LRRC37A4P NSF
Taking other prescription medications 2.7 3 1 3.0 0.00 1.0e+00 SH2B3 XBP1 ZNF318
Age when periods started (menarche) 1.6 3 0 0.0 0.00 1.0e+00 LRRC37A4P NEIL2 SLC22A5
Heel bone mineral density (BMD) T-score, automated (left) 3.4 7 5 15.2 0.16 7.2e-01 ACP2 C6orf174 CYB5D1 ERI1 NEIL2 OVOL1 WNT2B
High blood pressure 16.3 49 38 115.2 0.98 6.1e-36 ABCA12 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 C6orf174 CDK10 CENPW CLCN6 CWF19L2 CYB5D1 DBR1 ERI1 FES FGF11 FMNL1 GTF2B KCNK3 KIAA1199 LIME1 LRRC34 LRRC37A4P LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 OVOL1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 UBL3 WNT2B XBP1 ZBTB46 ZNF318
Hayfever, allergic rhinitis or eczema 1.9 5 2 6.1 -0.14 8.3e-01 C6orf106 LIME1 MPI OVOL1 SLC22A5
Supplements: Glucosamine 1.1 1 0 0.0 0.00 1.0e+00 MPI
Medication: Atenolol 7.0 5 2 6.1 0.99 1.9e-03 ARHGAP42 C4orf22 FES NCOA1 SH2B3
Medication: Levothyroxine sodium 3.3 2 2 6.1 0.00 1.0e+00 ERI1 SH2B3
Sitting height 1.8 12 7 21.2 0.28 3.8e-01 C6orf106 CENPW FGF11 GTF2B KIAA1199 LRRC37A4P NSF PIGV RP11-1055B8.4 SLC22A5 SLC35F6 SLC4A7
High blood pressure (mother) 7.9 15 4 12.1 0.98 2.0e-10 AGT ARHGAP42 C4orf22 C6orf174 CDK10 CENPW CLCN6 DBR1 FES LSP1 NT5C2 PIGV SLC4A7 TNNT3 ZNF318
Body mass index (BMI) 1.8 7 4 12.1 0.77 4.3e-02 C6orf106 ERI1 GTF2B KCNK3 KIAA1199 NEIL2 NT5C2
Impedance of leg (left) 2.6 16 11 33.3 -0.01 9.7e-01 ARHGAP42 C6orf106 ERI1 FES FMNL1 KCNK3 KIAA1199 LRRC37A4P MYO9B NEIL2 NSF NT5C2 SLC22A5 SLC35F6 WNT2B ZNF318
Leg predicted mass (left) 2.3 13 6 18.2 0.12 7.0e-01 ARHGAP42 C6orf106 CENPW ERI1 FES KCNK3 KIAA1199 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Trunk fat mass 2.1 9 4 12.1 0.12 7.5e-01 C6orf106 DBR1 KCNK3 KIAA1199 LRRC37A4P NSF NT5C2 RP11-138A9.1 WNT2B
Waist circumference 1.7 5 3 9.1 0.58 3.1e-01 C6orf106 C6orf174 KCNK3 KIAA1199 MPI
Past tobacco smoking 1.4 1 0 0.0 0.00 1.0e+00 SH2B3
Alcohol usually taken with meals 1.4 2 0 0.0 0.00 1.0e+00 FES FGF11
Nervous feelings 3.2 7 4 12.1 -0.42 3.5e-01 C1GALT1 ERI1 FMNL1 LRRC37A4P NEIL2 NSF NT5C2
Frequency of tenseness / restlessness in last 2 weeks 2.7 4 3 9.1 -0.98 2.4e-02 FMNL1 LRRC37A4P NSF NT5C2
Hearing difficulty/problems with background noise 2.5 3 1 3.0 0.00 1.0e+00 LRRC37A4P NSF ZNF318
Hair/balding pattern: Pattern 2 3.1 4 2 6.1 -0.90 1.0e-01 C4orf22 FMNL1 LRRC37A4P NSF
Forced vital capacity (FVC) 2.7 9 5 15.2 0.19 6.3e-01 ABCA12 ACP2 CENPW FMNL1 LRRC37A4P NCOA1 NSF RP11-1055B8.4 WNT2B
Heel bone mineral density (BMD) T-score, automated (right) 3.4 9 4 12.1 0.28 4.7e-01 ACP2 ARHGAP42 C6orf174 CYB5D1 ERI1 NEIL2 OVOL1 WNT2B XBP1
Ever unenthusiastic/disinterested for a whole week 1.8 1 0 0.0 0.00 1.0e+00 LRRC37A4P
Mouth/teeth dental problems 1.5 1 0 0.0 0.00 1.0e+00 ERI1
Heart attack 2.1 2 1 3.0 0.00 1.0e+00 FES SH2B3
Allergy 2.0 5 2 6.1 0.10 8.8e-01 C6orf106 FES LIME1 OVOL1 SLC22A5
Diabetes (self-reported) 2.1 2 0 0.0 0.00 1.0e+00 C1GALT1 ZBTB46
Medication: Ramipril 5.5 6 1 3.0 0.99 2.7e-05 ARHGAP42 C6orf106 DBR1 FES NCOA1 TNNT3
Medication: Simvastatin 3.4 3 1 3.0 0.00 1.0e+00 DBR1 FES PIGV
Illnesses of siblings 4.0 4 0 0.0 -0.99 1.1e-02 ARHGAP42 CLCN6 FES SH2B3
Neuroticism score 3.5 5 5 15.2 -0.98 3.0e-03 ERI1 FMNL1 LRRC37A4P NEIL2 NSF
Weight 2.0 10 5 15.2 0.30 4.1e-01 C6orf106 ERI1 KCNK3 KIAA1199 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 WNT2B
Impedance of arm (right) 2.7 15 8 24.2 -0.17 5.4e-01 C6orf106 ERI1 FGF11 FMNL1 KIAA1199 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF SH2B3 SLC4A7 TNNT3 WNT2B
Arm fat percentage (right) 1.9 9 3 9.1 0.33 3.9e-01 ACE C6orf106 CDK10 CLCN6 ERI1 FGF11 KCNK3 NT5C2 RP11-138A9.1
Trunk fat-free mass 2.6 16 10 30.3 0.10 7.1e-01 ARHGAP42 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Hip circumference 2.0 9 5 15.2 -0.03 9.4e-01 C6orf106 CLCN6 DBR1 ERI1 KCNK3 KIAA1199 NT5C2 RP11-138A9.1 SH2B3
Time employed in main current job 1.6 1 0 0.0 0.00 1.0e+00 LRRC37A4P
Father's age at death 2.8 5 2 6.1 -1.00 5.0e-05 ERI1 FES MPI SH2B3 SLC22A5
Worrier / anxious feelings 3.0 7 3 9.1 -0.46 3.0e-01 C1GALT1 ERI1 FMNL1 LRRC37A4P NEIL2 NSF NT5C2
Hair/balding pattern: Pattern 3 4.5 5 4 12.1 -0.79 1.1e-01 C4orf22 CENPW FMNL1 LRRC37A4P NSF
Number of live births 1.9 1 0 0.0 0.00 1.0e+00 LRRC37A4P
Forced expiratory volume in 1-second (FEV1) 3.0 9 5 15.2 0.05 8.9e-01 ABCA12 ARHGAP42 C1GALT1 ERI1 FMNL1 LRRC37A4P NCOA1 NSF RP11-1055B8.4
Qualifications: A levels/AS levels or equivalent 1.4 2 0 0.0 0.00 1.0e+00 LRRC37A4P NSF
Mouth/teeth dental problems: Dentures 1.3 2 0 0.0 0.00 1.0e+00 ERI1 RP11-1055B8.4
Asthma 2.1 1 1 3.0 0.00 1.0e+00 SLC22A5
Medication: Ibuprofen (e.g. Nurofen) 1.9 3 0 0.0 0.00 1.0e+00 FMNL1 LRRC37A4P NSF
Medication: Cholesterol lowering 3.1 3 1 3.0 0.00 1.0e+00 ARHGAP42 FES PIGV
Illnesses of mother 4.7 4 1 3.0 -0.97 2.7e-02 AGT ARHGAP42 FES SLC7A1
Forced expiratory volume in 1-second (FEV1), Best measure 2.7 7 3 9.1 0.16 7.3e-01 C1GALT1 ERI1 FMNL1 LRRC37A4P NCOA1 NSF RP11-1055B8.4
Impedance of arm (left) 2.9 15 9 27.3 -0.16 5.6e-01 C6orf106 ERI1 FGF11 FMNL1 KIAA1199 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF SH2B3 SLC4A7 TNNT3 WNT2B
Arm fat mass (right) 1.8 7 3 9.1 0.51 2.4e-01 C6orf106 ERI1 KCNK3 KIAA1199 NEIL2 NT5C2 WNT2B
Trunk predicted mass 2.6 16 10 30.3 0.10 7.1e-01 ARHGAP42 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Standing height 2.2 19 12 36.4 -0.14 5.7e-01 ACP2 C6orf106 CENPW ERI1 FGF11 GTF2B LRRC37A4P MGRN1 NCOA1 NSF PIGV RP11-1055B8.4 SH2B3 SLC22A5 SLC35F6 SLC4A7 UBL3 WNT2B ZNF318
Tense / 'highly strung' 1.9 2 0 0.0 0.00 1.0e+00 ERI1 NT5C2
Hair/balding pattern: Pattern 4 6.8 7 6 18.2 0.65 1.1e-01 C4orf22 CDK10 CENPW FMNL1 LRRC37A4P NSF XBP1
Birth weight of first child 2.9 5 2 6.1 -0.99 1.1e-03 CLCN6 FES GTF2B MPI SH2B3
Peak expiratory flow (PEF) 2.5 5 3 9.1 -0.35 5.7e-01 ABCA12 C1GALT1 ERI1 LRRC37A4P NSF
Qualifications: O levels/GCSEs or equivalent 1.7 2 0 0.0 0.00 1.0e+00 ERI1 MPI
Blood clot in the leg (DVT) 1.8 1 0 0.0 0.00 1.0e+00 CYB5D1
Medication: Paracetamol 2.4 2 1 3.0 0.00 1.0e+00 LRRC37A4P NSF
Headache pain in last month 2.7 3 3 9.1 0.00 1.0e+00 FMNL1 LRRC37A4P NSF
Medication for cholesterol, blood pressure or diabetes 6.8 13 5 15.2 -0.99 4.0e-10 ACE ACP2 ARHGAP42 C4orf22 CLCN6 CWF19L2 FES KIAA1199 PLCB1 SH2B3 SLC4A7 WNT2B ZBTB46
Gout (self-reported) 2.2 2 1 3.0 0.00 1.0e+00 OVOL1 SH2B3
Hypothyroidism/myxoedema (self-reported) 3.4 2 2 6.1 0.00 1.0e+00 ERI1 SH2B3
Medication: Amlodipine 8.6 13 7 21.2 0.99 1.3e-11 ACP2 ARHGAP42 C6orf174 CLCN6 FES KCNK3 KIAA1199 LSP1 OVOL1 SLC35F6 TNNT3 WNT2B ZNF318
Birth weight 2.4 4 3 9.1 -0.98 1.6e-02 FES NT5C2 SH2B3 TNNT3
High blood pressure (siblings) 6.2 10 2 6.1 0.98 2.7e-07 ACP2 ARHGAP42 C6orf174 CENPW CLCN6 FES KIAA1199 LSP1 SH2B3 TNNT3
Forced vital capacity (FVC), Best measure 2.5 7 5 15.2 0.46 3.0e-01 ACP2 CENPW FMNL1 LRRC37A4P NCOA1 NSF RP11-1055B8.4
Body fat percentage 2.2 12 5 15.2 0.26 4.2e-01 C6orf106 CDK10 DBR1 ERI1 FGF11 FMNL1 KCNK3 LRRC37A4P MYO9B NSF RP11-138A9.1 WNT2B
Leg fat percentage (right) 1.9 8 3 9.1 0.26 5.4e-01 C6orf106 CLCN6 ERI1 GTF2B KCNK3 MYO9B RP11-138A9.1 WNT2B
Arm fat-free mass (right) 2.4 14 6 18.2 0.16 6.0e-01 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Comparative body size at age 10 1.7 4 1 3.0 0.75 2.5e-01 ERI1 OVOL1 WNT2B ZNF318
Worry too long after embarrassment 1.7 2 0 0.0 0.00 1.0e+00 ERI1 LRRC37A4P
Wheeze or whistling in the chest in last year 1.6 1 0 0.0 0.00 1.0e+00 ZNF318
Qualifications: College or University degree 1.4 4 2 6.1 -0.14 8.6e-01 GTF2B LRRC37A4P NSF RP11-1055B8.4
Medication for pain relief, constipation, heartburn 2.8 4 1 3.0 -0.44 5.6e-01 ACE C6orf106 KIAA1199 LRRC37A4P
Neck or shoulder pain in last month 1.6 1 0 0.0 0.00 1.0e+00 CENPW
Medication: Blood pressure 9.9 20 11 33.3 0.97 2.3e-13 ACE ACP2 ARHGAP42 C4orf22 CDK10 CLCN6 CWF19L2 ERI1 FES GTF2B KIAA1199 LSP1 MPI PLCB1 SH2B3 SLC4A7 TNNT3 UBL3 WNT2B ZBTB46
Angina (self-reported) 2.5 1 1 3.0 0.00 1.0e+00 FES
Medication: Ibuprofen 1.8 2 0 0.0 0.00 1.0e+00 FMNL1 LRRC37A4P
Medication: Allopurinol 2.3 4 1 3.0 0.98 1.9e-02 CYB5D1 OVOL1 PIGV SH2B3
Medication: Seretide 50 evohaler 1.3 1 1 3.0 0.00 1.0e+00 SLC22A5
Mean time to correctly identify matches 1.5 3 1 3.0 0.00 1.0e+00 FES FGF11 SH2B3
Reproduciblity of spirometry measurement using ERS/ATS criteria 1.3 1 0 0.0 0.00 1.0e+00 FMNL1
Whole body fat mass 1.9 8 3 9.1 0.06 8.9e-01 C6orf106 DBR1 ERI1 KCNK3 KIAA1199 NT5C2 RP11-138A9.1 WNT2B
Leg fat mass (right) 1.9 8 3 9.1 0.35 4.0e-01 C6orf106 ERI1 KCNK3 KIAA1199 NEIL2 NT5C2 RP11-138A9.1 WNT2B
Arm predicted mass (right) 2.4 14 6 18.2 0.16 5.8e-01 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Pulse rate, automated reading 1.5 4 0 0.0 -0.55 4.5e-01 ACP2 C4orf22 C6orf106 RP11-1055B8.4
Alcohol intake frequency. 1.5 3 1 3.0 0.00 1.0e+00 LRRC37A4P MPI NSF
Comparative height size at age 10 2.3 14 7 21.2 0.16 5.8e-01 ACP2 C6orf106 CENPW GTF2B KIAA1199 LRRC37A4P NCOA1 NSF NT5C2 PIGV RP11-1055B8.4 SH2B3 SLC22A5 WNT2B
Suffer from 'nerves' 1.9 3 0 0.0 0.00 1.0e+00 FMNL1 LRRC37A4P NSF
Overall health rating 1.6 3 0 0.0 0.00 1.0e+00 C6orf106 ERI1 RP11-1055B8.4
Age at last live birth 1.7 1 0 0.0 0.00 1.0e+00 ERI1
Medication: Aspirin 3.7 3 1 3.0 0.00 1.0e+00 AGT FES SH2B3
Supplements: Vitamin C 1.4 1 0 0.0 0.00 1.0e+00 NSF
Hypertension (Self-reported) 16.4 49 38 115.2 0.98 6.8e-37 ABCA12 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 C6orf174 CDK10 CENPW CLCN6 CWF19L2 CYB5D1 DBR1 ERI1 FES FGF11 FMNL1 GTF2B KCNK3 KIAA1199 LIME1 LRRC34 LRRC37A4P LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 OVOL1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 UBL3 WNT2B XBP1 ZBTB46 ZNF318
Gastro-oesophageal reflux (gord) / gastric reflux (Self-reported) 2.1 2 0 0.0 0.00 1.0e+00 C6orf106 FMNL1
Illnesses of father: Heart disease 2.5 3 1 3.0 0.00 1.0e+00 DBR1 FES SH2B3
Smoking status: Previous 1.4 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.7 4 2 6.1 -0.42 5.8e-01 C6orf106 GTF2B MGRN1 SLC22A5
Whole body fat-free mass 2.5 15 8 24.2 0.08 7.8e-01 ARHGAP42 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Leg fat-free mass (right) 2.4 13 7 21.2 0.11 7.3e-01 ARHGAP42 C6orf106 CENPW ERI1 FES KCNK3 KIAA1199 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Arm fat percentage (left) 1.9 7 4 12.1 0.36 4.3e-01 C6orf106 CDK10 ERI1 FGF11 KCNK3 NT5C2 RP11-138A9.1
Average weekly red wine intake 1.1 1 0 0.0 0.00 1.0e+00 MPI
Handedness (chirality/laterality): Left-handed 2.0 2 1 3.0 0.00 1.0e+00 LRRC37A4P NSF
Mood swings 2.8 4 3 9.1 0.76 2.4e-01 ACP2 FMNL1 LRRC37A4P NSF
Loneliness, isolation 1.9 2 0 0.0 0.00 1.0e+00 LRRC37A4P SH2B3
Long-standing illness, disability or infirmity 1.8 1 0 0.0 0.00 1.0e+00 DBR1
Diabetes diagnosed by doctor 2.6 5 1 3.0 0.99 8.8e-04 ACE C1GALT1 DBR1 RP11-138A9.1 ZBTB46
Mouth/teeth dental problems: Mouth ulcers 1.9 2 1 3.0 0.00 1.0e+00 LRRC37A4P SH2B3
Medication for cholesterol 10.9 26 6 18.2 -0.99 5.3e-23 ACE AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 C6orf174 CDK10 CENPW CLCN6 CWF19L2 DBR1 FES KIAA1199 LIME1 LRRC37A4P LSP1 MGRN1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 TNNT3 WNT2B ZBTB46
Back pain experienced in last month 1.7 1 0 0.0 0.00 1.0e+00 C6orf106
Breast cancer (self-reported) 2.1 2 1 3.0 0.00 1.0e+00 LRRC37A4P SLC4A7
Asthma (self-reported) 2.0 1 1 3.0 0.00 1.0e+00 SLC22A5
Medication: Aspirin 3.6 2 1 3.0 0.00 1.0e+00 CDK10 FES
Medication: Gliclazide 1.4 1 0 0.0 0.00 1.0e+00 DBR1
Illnesses of father: None of the above (group 1) 3.2 2 1 3.0 0.00 1.0e+00 FES SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.7 5 3 9.1 -0.08 9.0e-01 C1GALT1 ERI1 FMNL1 LRRC37A4P NSF
Whole body water mass 2.5 16 8 24.2 0.12 6.7e-01 ARHGAP42 C6orf106 CENPW FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Leg predicted mass (right) 2.3 13 7 21.2 0.11 7.3e-01 ARHGAP42 C6orf106 CENPW ERI1 FES KCNK3 KIAA1199 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Arm fat mass (left) 1.8 7 3 9.1 0.61 1.5e-01 C6orf106 ERI1 KCNK3 KIAA1199 NEIL2 NT5C2 RP11-138A9.1
Number of self-reported non-cancer illnesses 4.6 8 1 3.0 0.99 4.5e-07 CWF19L2 CYB5D1 KIAA1199 LIME1 MYO9B SH2B3 SLC22A5 ZNF318
Average weekly champagne plus white wine intake 1.8 2 0 0.0 0.00 1.0e+00 LRRC37A4P NSF
Miserableness 2.4 5 3 9.1 -0.61 2.8e-01 ACP2 ERI1 FMNL1 LRRC37A4P NSF
Guilty feelings 2.0 3 1 3.0 0.00 1.0e+00 ACP2 LRRC37A4P NEIL2
Eye problems/disorders: Glaucoma 1.5 1 0 0.0 0.00 1.0e+00 ACP2
Supplements: Fish oil (including cod liver oil) 1.1 1 0 0.0 0.00 1.0e+00 ERI1
High cholesterol (Self-reported) 2.9 3 2 6.1 0.00 1.0e+00 ARHGAP42 CWF19L2 PIGV
Medication: Bendroflumethiazide 10.7 26 9 27.3 0.99 2.7e-22 ACP2 ARHGAP42 C1GALT1 C6orf174 CDK10 CLCN6 CWF19L2 ERI1 FES FGF11 KIAA1199 LSP1 MGRN1 MPI MYO9B NEIL2 PIGV PLCB1 SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 WNT2B ZNF318
Medication: Paracetamol 2.3 2 1 3.0 0.00 1.0e+00 LRRC37A4P NSF
Medication: Lisinopril 5.2 5 0 0.0 1.00 3.9e-04 ACP2 ARHGAP42 CDK10 MPI SH2B3
Illnesses of father: High blood pressure 5.6 9 1 3.0 0.97 1.1e-05 ACE ACP2 ARHGAP42 C4orf22 CDK10 FES NCOA1 PLCB1 SH2B3
Ever smoked 1.2 1 0 0.0 0.00 1.0e+00 SH2B3
Basal metabolic rate 2.4 11 7 21.2 0.27 4.3e-01 C6orf106 CENPW ERI1 KCNK3 KIAA1199 MYO9B NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6
Leg fat percentage (left) 1.9 7 2 6.1 0.19 6.9e-01 C6orf106 CLCN6 ERI1 GTF2B KCNK3 RP11-138A9.1 WNT2B
Arm fat-free mass (left) 2.4 16 6 18.2 0.24 3.7e-01 C6orf106 CENPW ERI1 FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7
Average weekly beer plus cider intake 1.6 1 0 0.0 0.00 1.0e+00 ERI1
Irritability 2.3 4 3 9.1 -1.00 2.2e-03 ERI1 LRRC37A4P NEIL2 NSF
Risk taking 1.6 1 0 0.0 0.00 1.0e+00 KCNK3
Diastolic blood pressure, automated reading 9.8 31 17 51.5 0.95 3.4e-17 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf174 CENPW CLCN6 CYB5D1 DBR1 ERI1 FES FMNL1 GTF2B KIAA1199 LIME1 LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 OVOL1 PIGV SH2B3 SLC22A5 TNNT3 WNT2B
Myopia 1.6 1 0 0.0 0.00 1.0e+00 C1GALT1
Vascular/heart problems diagnosed by doctor 15.7 48 32 97.0 -0.98 1.8e-33 ABCA12 ACE ACP2 AGT ARHGAP42 C1GALT1 C4orf22 C6orf106 C6orf174 CDK10 CENPW CLCN6 CWF19L2 CYB5D1 DBR1 ERI1 FES FGF11 FMNL1 GTF2B KCNK3 KIAA1199 LIME1 LRRC34 LSP1 MGRN1 MPI MYO9B NCOA1 NEIL2 NSF NT5C2 OVOL1 PIGV PLCB1 RP11-1055B8.4 RP11-138A9.1 SH2B3 SLC22A5 SLC35F6 SLC4A7 SLC7A1 TNNT3 UBL3 WNT2B XBP1 ZBTB46 ZNF318
Cholesterol lowering medication 3.2 4 1 3.0 0.99 1.2e-02 DBR1 MGRN1 PIGV RP11-138A9.1
Pain experienced in last month 1.9 2 0 0.0 0.00 1.0e+00 LRRC37A4P SH2B3
Basal cell carcinoma (self-reported) 1.4 1 1 3.0 0.00 1.0e+00 CDK10
Heart attack/myocardial infarction (self-reported) 2.1 2 1 3.0 0.00 1.0e+00 FES SH2B3
Deep venous thrombosis (DVT) (self-reported) 1.7 1 0 0.0 0.00 1.0e+00 CYB5D1
Heart disease (siblings) 2.2 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 2.9 17 10 30.3 -0.20 4.4e-01 ARHGAP42 C6orf106 CENPW ERI1 FMNL1 KCNK3 KIAA1199 LIME1 LRRC37A4P LSP1 MYO9B NEIL2 NSF NT5C2 SLC4A7 WNT2B ZNF318
Leg fat mass (left) 1.8 6 3 9.1 0.39 4.4e-01 C6orf106 ERI1 KCNK3 KIAA1199 NT5C2 WNT2B
Arm predicted mass (left) 2.4 16 6 18.2 0.25 3.6e-01 C6orf106 CENPW ERI1 FGF11 FMNL1 KCNK3 KIAA1199 LIME1 MYO9B NCOA1 NEIL2 NT5C2 SH2B3 SLC22A5 SLC35F6 SLC4A7

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 10 0.2865 1.97
GTEx Adipose Visceral Omentum 5 0.2456 2.04
GTEx Adrenal Gland 2 0.1373 1.97
GTEx Artery Aorta 15 0.5039 2.10
GTEx Artery Coronary 0 0.0000 1.90
GTEx Artery Tibial 14 0.3722 1.97
GTEx Brain Caudate basal ganglia 3 0.3261 1.89
GTEx Brain Cerebellar Hemisphere 2 0.1343 1.93
GTEx Brain Cerebellum 6 0.3027 1.93
GTEx Brain Cortex 3 0.2899 2.00
GTEx Brain Frontal Cortex BA9 4 0.4329 2.19
GTEx Brain Hippocampus 1 0.1908 1.90
GTEx Brain Hypothalamus 2 0.3390 1.96
GTEx Brain Nucleus accumbens basal ganglia 0 0.0000 1.98
GTEx Brain Putamen basal ganglia 0 0.0000 1.83
GTEx Breast Mammary Tissue 8 0.4053 2.06
GTEx Breast Mammary Tissue (Male) 5 0.4191 2.05
GTEx Breast Mammary Tissue (Female) 6 0.3650 2.00
GTEx Cells EBV-transformed lymphocytes 2 0.1405 2.00
GTEx Cells Transformed fibroblasts 11 0.2620 1.93
GTEx Colon Sigmoid 2 0.1368 2.01
GTEx Colon Transverse 5 0.2422 2.00
GTEx Esophagus Gastroesophageal Junction 0 0.0000 1.95
GTEx Esophagus Mucosa 13 0.3916 1.98
GTEx Esophagus Muscularis 10 0.3094 1.99
GTEx Heart Atrial Appendage 4 0.2533 2.05
GTEx Heart Left Ventricle 3 0.1961 1.98
GTEx Liver 0 0.0000 1.75
GTEx Lung 8 0.2785 2.01
GTEx Muscle Skeletal 8 0.2768 1.95
GTEx Nerve Tibial 9 0.2083 1.93
GTEx Ovary 4 0.4405 2.20
GTEx Pancreas 5 0.3064 2.07
GTEx Pituitary 2 0.1794 1.92
GTEx Prostate 3 0.3593 2.14
GTEx Skin Not Sun Exposed Suprapubic 12 0.4880 2.05
GTEx Skin Sun Exposed Lower leg 13 0.3571 1.99
GTEx Small Intestine Terminal Ileum 0 0.0000 2.12
GTEx Spleen 2 0.1417 1.91
GTEx Stomach 2 0.1376 2.04
GTEx Testis 8 0.2536 2.02
GTEx Thyroid 14 0.3501 1.95
GTEx Uterus 1 0.1764 2.12
GTEx Vagina 2 0.3150 1.91
GTEx Whole Blood 6 0.3011 1.92
METSIM Adipose 12 0.2603 1.80
NTR Blood 4 0.1665 1.83
ROSMAP Brain Pre-frontal Cortex 12 0.2733 2.02
YFS Blood 12 0.2599 1.75
CommonMind Brain Pre-frontal Cortex 15 0.2791 1.88
TCGA Breast Tumor 3 0.3911 2.07
TCGA Breast Normal 8 0.1902 1.78
TCGA Ovarian Tumor 7 0.2396 1.73
TCGA Prostate Tumor 3 0.0867 1.76